We Venture Capital

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

Oxford Cancer Analytics develops an AI-based platform for early cancer detection via blood testing. It analyzes liquid biopsy results from DNA, proteins, epigenetics, epidemiology, and medical history, enabling healthcare providers to identify cancers early and initiate curative treatment.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Capitainer is a Swedish medical device company that develops volumetric blood collection devices for fixed-volume dried blood spots collected at home. The device enables patients to remotely collect a predefined blood volume, which can be mailed to a laboratory for analysis. The technology aims to reduce patient travel and healthcare resources required for blood sampling, while delivering improved accuracy over conventional methods and offering cost and environmental savings for healthcare providers handling large volumes of samples. Founded in 2016 and based in Stockholm, Capitainer focuses on enabling convenient, safe, and reliable remote blood collection for quantitative testing.

Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.